See how the Nu-Derm System can transform skin to look and act younger and healthier.1
Nu-Derm Before & After *
Nu-Derm Before & After †
Nu-Derm Before & After *
Nu-Derm Before & After *
*Nu-Derm Normal to Oily System used with 0.025% tretinoin cream.
†Nu-Derm Normal to Oily System used with 0.1% tretinoin cream.
Photos have not been retouched. Results may vary.
Nu-Derm System used in conjunction with tretinoin. Tretinoin is indicated for topical application in the treatment of acne vulgaris.
Renew Your Skin
The Nu-Derm System with tretinoin‡ delivers visible results you’ll love.
Clinically Significant Improvements in the Signs of Skin Aging
2x greater improvement in all measurements of fine lines and wrinkles vs stand-alone treatments3,4
- Clinically significant improvement was seen in facial fine wrinkles, fine wrinkles around the mouth, and loss of elasticity
*Tretinoin is indicated for topical application in the treatment of acne vulgaris.
Results You Can See and Feel
In 2 separate studies, a majority of patients reported improvement in the following parameters at week 12 after using the Nu-Derm System with tretinoin for melasma2,5 §:
Efforts to hide skin discoloration
Focus on skin discoloration by others
Effects on social and leisure activities
Transform Your Skin at Every Phase
There are 4 phases to skin transformation. Depending on your skin’s response to the treatment, each phase may last anywhere from 1 week to several weeks.
‡Tretinoin cream is indicated for topical application in the treatment of acne vulgaris.
§Results from one study for Nu-Derm Normal to Oily System used with 0.025% tretinoin cream and another study for Nu-Derm Normal to Oily System used with 0.05% tretinoin cream.
‖If you experience excessive itching, dryness, or redness, discontinue use of the system and contact your physician.
¶When used under the guidance of your physician, maintenance ensures lasting results.
References: 1. OMP, Inc. Data on file. 2. Gold M, Rendon M, DiBernardo B, Bruce S, Investigators. A multi-center study to evaluate the efficacy and tolerability of an Obagi Nu-Derm® treatment regimen with tretinoin cream USP 0.05% in the treatment of moderate to severe melasma. 24-week final analysis, November 2011. OMP, Inc. Data on file. 3. Herndon JH Jr, Stephens TJ, Sigler ML. Efficacy of a tretinoin/hydroquinone-based skin health system in the treatment of facial photodamage. Cosmet Dermatol. 2006;19(4):255-262. 4. Herndon JH Jr, Blum SL, Sigler ML, Stephens TJ, Investigators. Controlled usage study to evaluate skin health restoration systems in improving the condition of photodamaged skin. March 2003. OMP, Inc. Data on file. 5. Grimes P, Investigator. A single center study to evaluate the efficacy and tolerability of an Obagi Nu-Derm® treatment regimen with tretinoin cream 0.025% in the treatment of mild or moderate melasma. 24-week final analysis, September 2011. OMP, Inc. Data on file.
Important Safety Information for Clear, Blender, and Sunfader
People with prior history of sensitivity or allergic reaction to this product or any of its ingredients should not use it. The safety of topical hydroquinone use during pregnancy or in children (12 years and under) has not been established.
Avoid contact with eyes, nose, mouth, or lips. In case of accidental contact, patient should rinse eyes, nose, mouth, or lips with water and contact physician.
Sunscreen use is an essential aspect of hydroquinone therapy because even minimal sunlight exposure sustains melanocytic activity.
Contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.
PRECAUTIONS (ALSO SEE WARNINGS):
Treatment should be limited to relatively small areas of the body at one time since some patients experience a transient skin reddening and a mild burning sensation, which does not preclude treatment.
Pregnancy Category C: Animal reproduction studies have not been conducted with topical hydroquinone. It is also not known whether hydroquinone can cause fetal harm when used topically on a pregnant woman or affect reproductive capacity. It is not known to what degree, if any, topical hydroquinone is absorbed systemically. Topical hydroquinone should be used on pregnant women only when clearly indicated.
Nursing Mothers: It is not known whether topical hydroquinone is absorbed or excreted in human milk. Caution is advised when topical hydroquinone is used by a nursing mother.
Pediatric Usage: Safety and effectiveness in children below the age of 12 years have not been established.
Use of the product should be discontinued if hypersensitivity to any of the ingredients is noted.